Vireo Growth Inc.
- VREOF · OTC
- Pharmaceutical Preparations
- Minneapolis, MN
- 612 employees
- CIK 0001771706
Updated from SEC filings through
Top things to know
Executives
- John Mazarakis Chief Executive Officer 4, 2025-12-30
- Tyson Macdonald Chief Financial Officer 4, 2025-12-30
- Joseph Duxbury Chief Accounting Officer 4, 2026-05-19
- Amber Holly Shimpa President 4, 2025-12-30
- Sean Michael Apfelbaum GC and Corporate Secretary 4, 2026-05-19
- Kyle Eugene Kingsley Co-Executive Chairman 4, 2025-12-30
What leadership is saying
“We believe the cannabis industry is entering a period where scale alone is no longer enough. The companies that create lasting value will be those that combine disciplined capital allocation, operational excellence, and the ability to integrate businesses efficiently. Every acquisition we announced during the quarter reflects that philosophy. Rather than pursuing growth for its own sake, we are building a diversified cannabis and agribusiness platform where each investment st”
Earnings press release (8-K Ex. 99.1), filed August 11, 2026
Vireo Growth Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Minneapolis, MN. It trades as VREOF on OTC. Revenue was $269M in the fiscal year ending December 31, 2025, +170.4% from the year before. It reported about 612 employees. John Mazarakis is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $269M 10-K, 2026-03-17 | $99.4M 10-K, 2026-03-17 | $88.1M 10-K, 2025-03-04 | $74.6M 10-K, 2024-04-01 | $54.4M 10-K, 2023-03-31 |
| Operating income | -$1.0M 10-K, 2026-03-17 | $13.6M 10-K, 2026-03-17 | $10.6M 10-K, 2025-03-04 | -$6.9M 10-K, 2024-04-01 | -$20.5M 10-K, 2023-03-31 |
| SG&A | $81.2M 10-K, 2026-03-17 | $28.1M 10-K, 2026-03-17 | $28.2M 10-K, 2025-03-04 | $33.8M 10-K, 2024-04-01 | $33.7M 10-K, 2023-03-31 |
| Net income | -$68.1M 10-K, 2026-03-17 | -$28.0M 10-K, 2026-03-17 | -$25.5M 10-K, 2025-03-04 | -$42.5M 10-K, 2024-04-01 | -$33.7M 10-K, 2023-03-31 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| John Mazarakis | Chief Executive Officer | 4, 2025-12-30 |
| Tyson Macdonald Strategy, Finance and M&A Executive | Chief Financial Officer | 4, 2025-12-30 |
| Joseph Duxbury | Chief Accounting Officer | 4, 2026-05-19 |
| Amber Holly Shimpa | President | 4, 2025-12-30 |
| Sean Michael Apfelbaum | GC and Corporate Secretary | 4, 2026-05-19 |
| Kyle Eugene Kingsley | Co-Executive Chairman | 4, 2025-12-30 |
What Vireo Growth Inc. does
Vireo Growth Inc. is a reporting issuer in Canada, with its securities listed for trading on the Canadian Securities Exchange (the “ CSE ”) under the symbol “VREO” and on the OTCQX under the symbol “VREOF”. Vireo Growth is a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Public float | $346M (as of June 30, 2025) | 10-K, March 17, 2026 |
|---|---|---|
| Reportable segments | 2 (period ending June 30, 2026) | 10-Q, August 14, 2026 |
| Latest proxy statement | Meeting May 29, 2026 (filed April 16, 2026) | DEF 14A, April 16, 2026 |
| Auditor | Davidson & Company LLP (Vancouver, BC) | Latest 10-K |
Recent 8-K events
- 8-K filed 2026-10-08
- Item 1.01 Entry into a material definitive agreement
- Item 1.02 Termination of a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-26
- Item 2.01 Completion of acquisition or disposition of assets
- Item 3.02 Unregistered sales of equity securities
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-18
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-08-13
- Item 1.01 Entry into a material definitive agreement
- Item 2.01 Completion of acquisition or disposition of assets
- Item 2.03 Creation of a direct financial obligation
- Item 3.02 Unregistered sales of equity securities
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-11
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-05
- Item 1.01 Entry into a material definitive agreement
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-07-30
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-07-27
- Item 8.01 Other events
- 8-K filed 2026-07-23
- Item 1.01 Entry into a material definitive agreement
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-06-18
- Item 1.01 Entry into a material definitive agreement
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Vireo Growth Inc.
- What does Vireo Growth Inc. do?
- In its own words, from Item 1 of its 10-K: "Vireo Growth Inc. is a reporting issuer in Canada, with its securities listed for trading on the Canadian Securities Exchange (the “ CSE ”) under the symbol “VREO” and on the OTCQX under the symbol “VREOF”. Vireo Growth is a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs."
- What is Vireo Growth Inc.'s revenue?
- $269M for the fiscal year ending December 31, 2025, from its 10-K filed March 17, 2026.
- Is Vireo Growth Inc. profitable?
- Vireo Growth Inc. reported net income of -$68.1M for the fiscal year ending December 31, 2025.
- How many employees does Vireo Growth Inc. have?
- About 612 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Vireo Growth Inc.?
- John Mazarakis, Chief Executive Officer, as named in a 4 filed December 30, 2025.
- Who is the CFO of Vireo Growth Inc.?
- Tyson Macdonald, Chief Financial Officer, as named in a 4 filed December 30, 2025.
- Where is Vireo Growth Inc. headquartered?
- Minneapolis, MN.
- What is Vireo Growth Inc.'s stock ticker?
- VREOF on OTC.
- What industry is Vireo Growth Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Vireo Growth Inc.'s website?
- vireogrowth.com. Investor relations: https://investors.vireogrowth.com/home/default.aspx.
- When does Vireo Growth Inc. report earnings next?
- November 13, 2026. Source: estimate_10q_cadence.
- Is Vireo Growth Inc. a public company?
- Yes. Vireo Growth Inc. files with the SEC under CIK 0001771706 and trades as VREOF.
- Who audits Vireo Growth Inc.?
- Davidson & Company LLP, Vancouver, BC, as named in its latest annual report (10-K).
- What is Vireo Growth Inc.'s public float?
- $346M as of June 30, 2025, as reported on the cover of its 10-K filed March 17, 2026.
- How many business segments does Vireo Growth Inc. report?
- 2 reportable segments for the period ending June 30, 2026, from its 10-Q filed August 14, 2026.
- When is Vireo Growth Inc.'s annual shareholder meeting?
- May 29, 2026, per its proxy statement (DEF 14A) filed April 16, 2026.